Inhibition of GSK3 by lithium, from single molecules to signaling networks

Frontiers in Molecular Neuroscience

Volumn , Issue JANUARY 2012, 2012, Pages

  Freland, Laure ^a   Beaulieu, Jean Martin ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CELL SURFACE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM SALT; NEUROLEPTIC AGENT; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

ANIMAL BEHAVIOR; ANTIDEPRESSANT ACTIVITY; ANTIMANIC ACTIVITY; ARTICLE; BIPOLAR DISORDER; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; IN VIVO STUDY; INTRACELLULAR SIGNALING; MENTAL DISEASE; MOLECULAR INTERACTION; NONHUMAN; PATHOGENESIS; SIGNAL TRANSDUCTION;

EID: 84856702223     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2012.00014     Document Type: Article

References (87)

1. Adli, M., Hollinde, D.L., Stamm, T., Wiethoff, K., Tsahuridu, M., Kirchheiner, J., Heinz, A., and Bauer, M. (2007). Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry 62, 1295-1302.
2. Alessi, D.R., and Cohen, P. (1998). Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8, 55-62.
3. Beaulieu, J.M. (2011). A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. Journal of psychiatry & neuroscience: JPN 36, 110011.
4. Beaulieu, J.M., and Caron, M.G. (2008). Looking at lithium: molecular moods and complex behaviour. Mol Interv 8, 230-241.
5. Beaulieu, J.M., Del'guidice, T., Sotnikova, T.D., Lemasson, M., and Gainetdinov, R.R. (2011). Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors. Frontiers in molecular neuroscience 4, 38.
6. Beaulieu, J.M., and Gainetdinov, R.R. (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63, 182-217.
7. Beaulieu, J.M., Gainetdinov, R.R., and Caron, M.G. (2009). Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49, 327-347.
8. Beaulieu, J.M., Marion, S., Rodriguiz, R.M., Medvedev, I.O., Sotnikova, T.D., Ghisi, V., Wetsel, W.C., Lefkowitz, R.J., Gainetdinov, R.R., and Caron, M.G. (2008). A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132, 125-136.
9. Beaulieu, J.M., Sotnikova, T.D., Marion, S., Lefkowitz, R.J., Gainetdinov, R.R., and Caron, M.G. (2005). An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261-273.
10. Beaulieu, J.M., Sotnikova, T.D., Yao, W.D., Kockeritz, L., Woodgett, J.R., Gainetdinov, R.R., and Caron, M.G. (2004). Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 101, 5099-5104.
11. Behrens, J., Jerchow, B.A., Wurtele, M., Grimm, J., Asbrand, C., Wirtz, R., Kuhl, M., Wedlich, D., and Birchmeier, W. (1998). Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280, 596-599.
12. Benedetti, F., Serretti, A., Colombo, C., Lorenzi, C., Tubazio, V., and Smeraldi, E. (2004). A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 368, 123-126.
13. Berridge, M.J., Downes, C.P., and Hanley, M.R. (1989). Neural and developmental actions of lithium: a unifying hypothesis. Cell 59, 411-419.
14. Birch, N.J. (1974). Letter: Lithium and magnesium-dependent enzymes. Lancet 2, 965-966.
15. Blanco, C., Laje, G., Olfson, M., Marcus, S.C., and Pincus, H.A. (2002). Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 159, 1005-1010.
16. Blasi, G., Napolitano, F., Ursini, G., Taurisano, P., Romano, R., Caforio, G., Fazio, L., Gelao, B., Di Giorgio, A., Iacovelli, L., Sinibaldi, L., Popolizio, T., Usiello, A., and Bertolino, A. (2011). DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 108, 1158-1163.
17. Bowden, C.L. (2000). Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry 61 Suppl 9, 35-40.
18. Cade, J.F. (1949). Lithium salts in the treatment of psychotic excitement. Med J Aust 2, 349-352.
19. Chalecka-Franaszek, E., and Chuang, D.M. (1999). Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 96, 8745-8750.
20. Chubb, J.E., Bradshaw, N.J., Soares, D.C., Porteous, D.J., and Millar, J.K. (2008). The DISC locus in psychiatric illness. Mol Psychiatry 13, 36-64.
21. Cipriani, A., Pretty, H., Hawton, K., and Geddes, J.R. (2005). Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 162, 1805-1819.
22. Cohen, P., and Frame, S. (2001). The renaissance of GSK3. Nat Rev Mol Cell Biol 2, 769-776.
23. Crawley, J.N. (2008). Behavioral phenotyping strategies for mutant mice. Neuron 57, 809-818.
24. Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M., and Hemmings, B.A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789.
25. Cryns, K., Shamir, A., Shapiro, J., Daneels, G., Goris, I., Van Craenendonck, H., Straetemans, R., Belmaker, R.H., Agam, G., Moechars, D., and Steckler, T. (2007). Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology 32, 881-891.
26. Cryns, K., Shamir, A., Van Acker, N., Levi, I., Daneels, G., Goris, I., Bouwknecht, J.A., Andries, L., Kass, S., Agam, G., Belmaker, H., Bersudsky, Y., Steckler, T., and Moechars, D. (2008). IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity. Neuropsychopharmacology 33, 674-684.
27. De Montigny, C., Grunberg, F., Mayer, A., and Deschenes, J.P. (1981). Lithium induces rapid relief of depression in tricyclic antidepressant drug non- responders. Br J Psychiatry 138, 252-256.
28. De Sarno, P., Li, X., and Jope, R.S. (2002). Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43, 1158-1164.
29. Eldar-Finkelman, H., and Krebs, E.G. (1997). Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proceedings of the National Academy of Sciences of the United States of America 94, 9660-9664.
30. Emamian, E.S., Hall, D., Birnbaum, M.J., Karayiorgou, M., and Gogos, J.A. (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36, 131-137.
31. Embi, N., Rylatt, D.B., and Cohen, P. (1980). Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107, 519-527.
32. Ferguson, S.S., Downey, W.E., 3rd, Colapietro, A.M., Barak, L.S., Menard, L., and Caron, M.G. (1996). Role of beta-arrestin in mediating agonist- promoted G protein-coupled receptor internalization. Science 271, 363-366.
33. Gould, T.D., Chen, G., and Manji, H.K. (2004). In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29, 32-38.
34. Gould, T.D., and Manji, H.K. (2002). Signaling networks in the pathophysiology and treatment of mood disorders. J Psychosom Res 53, 687-697.
35. Hughes, K., Nikolakaki, E., Plyte, S.E., Totty, N.F., and Woodgett, J.R. (1993). Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. Embo J 12, 803-808.
36. Jaaro-Peled, H., Hayashi-Takagi, A., Seshadri, S., Kamiya, A., Brandon, N.J., and Sawa, A. (2009). Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1- ErbB4 and DISC1. Trends in neurosciences 32, 485-495.
37. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S.Y., Huang, Q., Qin, J., and Su, B. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125-137.
38. Jope, R.S. (2011). Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Frontiers in molecular neuroscience 4, 16.
39. Kaidanovich-Beilin, O., Milman, A., Weizman, A., Pick, C.G., and Eldar-Finkelman, H. (2004). Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 55, 781-784.
40. Kaidanovich-Beilin, O., and Woodgett, J.R. (2011). GSK-3: Functional Insights from Cell Biology and Animal Models. Frontiers in molecular neuroscience 4, 40.
41. Kishida, S., Yamamoto, H., Ikeda, S., Kishida, M., Sakamoto, I., Koyama, S., and Kikuchi, A. (1998). Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. The Journal of biological chemistry 273, 10823-10826.
42. Klein, P.S., and Melton, D.A. (1996). A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93, 8455-8459.
43. Kremer, A., Louis, J.V., Jaworski, T., and Van Leuven, F. (2011). GSK3 and Alzheimer's Disease: Facts and Fiction. Frontiers in molecular neuroscience 4, 17.
44. Kvajo, M., Mckellar, H., Arguello, P.A., Drew, L.J., Moore, H., Macdermott, A.B., Karayiorgou, M., and Gogos, J.A. (2008). A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proceedings of the National Academy of Sciences of the United States of America 105, 7076-7081.
45. Law, A.J., Kleinman, J.E., Weinberger, D.R., and Weickert, C.S. (2007). Disease- associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Human molecular genetics 16, 129-141.
46. Lemmon, M.A., and Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134.
47. Li, X., Friedman, A.B., Zhu, W., Wang, L., Boswell, S., May, R.S., Davis, L.L., and Jope, R.S. (2007). Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biological psychiatry 61, 216-222.
48. Li, X., Zhu, W., Roh, M.S., Friedman, A.B., Rosborough, K., and Jope, R.S. (2004). In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 29, 1426-1431.
49. Liao, Y., and Hung, M.C. (2010). Physiological regulation of Akt activity and stability. Am J Transl Res 2, 19-42.
50. Liberman, Z., Plotkin, B., Tennenbaum, T., and Eldar-Finkelman, H. (2008).Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 and protein kinase C betaII in the diabetic fat tissue. Am J Physiol Endocrinol Metab 294, E1169-1177.
51. Lochhead, P.A., Kinstrie, R., Sibbet, G., Rawjee, T., Morrice, N., and Cleghon, V. (2006). A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. Molecular cell 24, 627-633.
52. Lohse, M.J., Benovic, J.L., Codina, J., Caron, M.G., and Lefkowitz, R.J. (1990). Beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science 248, 1547-1550.
53. Luttrell, L.M., Ferguson, S.S., Daaka, Y., Miller, W.E., Maudsley, S., Della Rocca, G.J., Lin, F., Kawakatsu, H., Owada, K., Luttrell, D.K., Caron, M.G., and Lefkowitz, R.J. (1999). Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283, 655-661.
54. Luttrell, L.M., and Gesty-Palmer, D. (2010). Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 62, 305-330.
55. Mao, Y., Ge, X., Frank, C.L., Madison, J.M., Koehler, A.N., Doud, M.K., Tassa, C., Berry, E.M., Soda, T., Singh, K.K., Biechele, T., Petryshen, T.L., Moon, R.T., Haggarty, S.J., and Tsai, L.H. (2009). Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 136, 1017-1031.
56. Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J.M., Gainetdinov, R.R., and Caron, M.G. (2008). Antagonism of dopamine D2 receptor/beta- arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A 105, 13656-13661.
57. Mines, M.A., Yuskaitis, C.J., King, M.K., Beurel, E., and Jope, R.S. (2010). GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PloS one 5, e9706.
58. Muller-Oerlinghausen, B., Felber, W., Berghofer, A., Lauterbach, E., and Ahrens, B. (2005). The impact of lithium long-term medication on suicidal behavior and mortality of bipolar patients. Arch Suicide Res 9, 307-319.
59. Neves-Pereira, M., Mundo, E., Muglia, P., King, N., Macciardi, F., and Kennedy, J.L. (2002). The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet 71, 651-655.
60. O'brien, W.T., Harper, A.D., Jove, F., Woodgett, J.R., Maretto, S., Piccolo, S., and Klein, P.S. (2004). Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 24, 6791-6798.
61. O'brien, W.T., Huang, J., Buccafusca, R., Garskof, J., Valvezan, A.J., Berry, G.T., and Klein, P.S. (2011). Glycogen synthase kinase-3 is essential for beta-arrestin-2 complex formation and lithium-sensitive behaviors in mice. The Journal of clinical investigation.
62. Pan, J.Q., Lewis, M.C., Ketterman, J.K., Clore, E.L., Riley, M., Richards, K.R., Berry-Scott, E., Liu, X., Wagner, F.F., Holson, E.B., Neve, R.L., Biechele, T.L., Moon, R.T., Scolnick, E.M., Petryshen, T.L., and Haggarty, S.J. (2011). AKT kinase activity is required for lithium to modulate mood- related behaviors in mice. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 36, 1397-1411.
63. Parker, P.J., Caudwell, F.B., and Cohen, P. (1983). Glycogen synthase from rabbit skeletal muscle; effect of insulin on the state of phosphorylation of the seven phosphoserine residues in vivo. Eur J Biochem 130, 227-234.
64. Phiel, C.J., and Klein, P.S. (2001). Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41, 789-813.
65. Rapoport, S.I., and Bosetti, F. (2002). Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Archives of general psychiatry 59, 592-596.
66. Roth, B.L., Sheffler, D.J., and Kroeze, W.K. (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3, 353-359.
67. Ryves, W.J., and Harwood, A.J. (2001). Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 280, 720-725.
68. Scheid, M.P., and Woodgett, J.R. (2001). PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2, 760-768.
69. Schmidt, H.D., and Duman, R.S. (2010). Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 35, 2378-2391.
70. Schou, M., Juel-Nielsen, N., Stromgren, E., and Voldby, H. (1954). The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 17, 250-260.
71. Serretti, A., Benedetti, F., Mandelli, L., Calati, R., Caneva, B., Lorenzi, C., Fontana, V., Colombo, C., and Smeraldi, E. (2008). Association between GSK-3beta -50T/C polymorphism and personality and psychotic symptoms in mood disorders. Psychiatry Res 158, 132-140.
72. Shaldubina, A., Johanson, R.A., O'brien, W.T., Buccafusca, R., Agam, G., Belmaker, R.H., Klein, P.S., Bersudsky, Y., and Berry, G.T. (2006). SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium- sensitive behavior. Mol Genet Metab 88, 384-388.
73. Snyder, S.H. (1976). The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 133, 197-202.
74. Spiegelberg, B.D., Dela Cruz, J., Law, T.H., and York, J.D. (2005). Alteration of lithium pharmacology through manipulation of phosphoadenosine phosphate metabolism. The Journal of biological chemistry 280, 5400-5405.
75. Stambolic, V., Ruel, L., and Woodgett, J.R. (1996). Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6, 1664-1668.
76. Stambolic, V., and Woodgett, J.R. (1994). Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J 303 (Pt 3), 701-704.
77. Sutherland, C., and Cohen, P. (1994). The alpha-isoform of glycogen synthase kinase-3 from rabbit skeletal muscle is inactivated by p70 S6 kinase or MAP kinase-activated protein kinase-1 in vitro. FEBS Lett 338, 37-42.
78. Sutherland, C., Leighton, I.A., and Cohen, P. (1993). Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 296 (Pt 1), 15-19.
79. Swift, J.L., Godin, A.G., Dore, K., Freland, L., Bouchard, N., Nimmo, C., Sergeev, M., De Koninck, Y., Wiseman, P.W., and Beaulieu, J.M. (2011). Quantification of receptor tyrosine kinase transactivation through direct dimerization and surface density measurements in single cells. Proc Natl Acad Sci U S A 108, 7016-7021.
80. Tondo, L., and Baldessarini, R.J. (2009). Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients. Epidemiol Psichiatr Soc 18, 179-183.
81. Valenstein, M., Mccarthy, J.F., Austin, K.L., Greden, J.F., Young, E.A., and Blow, F.C. (2006). What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 163, 1219-1225.
82. Waraich, R.S., Weigert, C., Kalbacher, H., Hennige, A.M., Lutz, S.Z., Haring, H.U., Schleicher, E.D., Voelter, W., and Lehmann, R. (2008). Phosphorylation of Ser357 of rat insulin receptor substrate-1 mediates adverse effects of protein kinase C-delta on insulin action in skeletal muscle cells. The Journal of biological chemistry 283, 11226-11233.
83. Williams, R.S., Cheng, L., Mudge, A.W., and Harwood, A.J. (2002). A common mechanism of action for three mood-stabilizing drugs. Nature 417, 292-295.
84. Williams, R.S.B., and Harwood, A.J. (2005). 3Li Lithium Metallotherapeutics, in Metallotherapeutic drugs and metal-based diagnostic agents: the use of metals in medicine, ed. M.a.T. Gielen, E. R. T. (Chichester, West Sussex, England: John Wieley & Sons Ltd.), 1-18.
85. Woodgett, J.R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. Embo J 9, 2431-2438.
86. Woodgett, J.R. (2001). Judging a protein by more than its name: GSK-3. Sci STKE 2001, RE12.
87. Zhang, F., Phiel, C.J., Spece, L., Gurvich, N., and Klein, P.S. (2003). Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278, 33067-33077.